Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of frailty on intra-hospital survival in older patients with COVID-19 infection: the importance of early identification. SEMI-COVID National Registry.

Revista clinica espanola·2023
Same author

Case of a 64-year old woman with hyponatremia and hydrocephalus.

Revista clinica espanola·2015
Same author

Guillain-Barré syndrome as first presentation of non-Hodgkin lymphoma.

Neurologia (Barcelona, Spain)·2012
Same author

Denervation hypertrophy in L5 radiculopathy.

Revue neurologique·2011
Same author

[Chagas: an emergent and unknown disease].

Revista clinica espanola·2011
Same author

[Dopaminergic malignant syndrome due to acute withdrawal of l-dopa].

Revista clinica espanola·2010

Related Experiment Video

Updated: May 15, 2026

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

[Acarbose and propofol: a dangerous combination?].

E Rocha-Honor1, F J Polo-Romero1, P Sánchez-Beteta1

  • 1Servicio de Medicina Interna, Hospital de Hellín, Hellín, Albacete, España.

Revista Espanola De Anestesiologia Y Reanimacion
|January 2, 2013
PubMed
Summary

Propofol can cause rare but serious liver injury (hepatotoxicity). This case highlights a potential interaction with acarbose, emphasizing careful pre-anesthetic evaluation for patients receiving propofol sedation.

Keywords:
AcarbosaAcarboseAdverse effectsEfectos secundariosHepatitisPropofol

Related Experiment Videos

Last Updated: May 15, 2026

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

Area of Science:

  • Hepatology
  • Anesthesiology
  • Pharmacology

Background:

  • Propofol is widely used for sedation in various procedures, including endoscopy and surgery.
  • Hepatotoxicity is a rare but serious adverse effect of propofol.
  • Acarbose is a common medication for type 2 diabetes management.

Observation:

  • A case report details a patient who developed acute hepatitis after propofol use during ophthalmology surgery.
  • The patient had a history of acarbose use, a drug also known to cause liver injury.
  • This suggests a potential synergistic or additive hepatotoxic effect between propofol and acarbose.

Findings:

  • The patient's acute hepatitis was diagnosed early and resolved without complications.
  • This case underscores the importance of considering concurrent medications when assessing propofol-induced hepatotoxicity.
  • The interaction between propofol and acarbose in causing hepatitis warrants further investigation.

Implications:

  • Enhanced pre-anesthetic evaluation is crucial for patients undergoing propofol sedation, especially those on medications like acarbose.
  • Early recognition and diagnosis of propofol-induced hepatotoxicity are key to successful management.
  • This case contributes to understanding rare drug-induced liver injury and informs clinical practice for patient safety.